ArticleBMC biotechnology2025
Anticancer effects of folic acid-functionalized covalent organic framework containing doxorubicin on SW480 colon cancer cells: a promising tool for drug targeted delivery.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dual-targeted glutathione-glutamate functionalized Bismuth-Niosomes hybrid nanosystem for co-delivery of doxorubicin and Pi3K inhibitor into U87 glioblastoma cells.Scientific reports · 2026Article
- Design, synthesis, and anticancer evaluation of a novel imine-linked covalent organic framework correlated to molecular docking and DFT insights.RSC advances · 2026Article
- A Porphyrinic Covalent Organic Polymer Nanoplatform for Carborane Delivery and Multifunctional Imaging-Guided Boron Neutron Capture Therapy of Breast Cancer.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Colorectal cancer is one of the deadliest forms of gastrointestinal cancer, with conventional treatments often facing significant limitations. As a result, new approaches, particularly in targeted drug delivery, have shown great promise. In this study, the COF-FA@DOX nanocarrier was developed, where covalent organic frameworks (COFs) were functionalized with folic acid (FA) and then loaded with Doxorubicin (DOX). The as-synthesized COF-FA@DOX nanocarrier was characterized using different techniques. To assess its anticancer effectiveness, MTT, flow cytometry, and scratch assays were conducted on SW480 and HUVEC cells to examine cell viability, cellular uptake, cell cycle progression, apoptosis, and cell migration, respectively. The obtained results demonstrated that the COF-FA@DOX nanocarrier was efficiently internalized by cancer cells and showed significantly higher cytotoxicity compared to other synthesized nanocarrier groups and free DOX drug. Moreover, the COF-FA@DOX nanocarrier caused cell cycle arrest, induced apoptosis, and inhibited cell migration at lower doses than the free DOX drug. Altogether, these findings suggest that the COF-FA@DOX nanocarrier is an effective and promising drug delivery system for DOX in colorectal cancer, potentially enhancing the therapeutic efficacy of DOX drug while minimizing side effects through targeted delivery. Further investigation is required to assess their efficacy in vivo and discover potential clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.